Publications by authors named "E Manesis"
Article Synopsis
- Patients with liver steatosis and diabetes may benefit from medications like Empagliflozin and Dulaglutide, but studies specifically comparing these drugs are lacking.
- This study involved 78 adults with type 2 diabetes and nonalcoholic fatty liver disease who received either Empagliflozin, Dulaglutide, or other treatments, focusing on liver fat reduction.
- Results showed the Empagliflozin group had greater reductions in liver fat compared to Dulaglutide and the control group, although weight loss occurred in all groups and no improvement in liver fibrosis was observed.*
Background And Aims: Hepatitis D virus (HDV) underdiagnosis remains common. We assessed the HDV screening and prevalence rates in HBsAg-positive patients seen at tertiary liver centres throughout Greece as well as factors affecting HDV diagnosis.
Methods: All adult HBsAg-positive patients seen within the last 5 years were included.
Purpose: Chronic liver disease (CLD) is considered one of the main causes of death. Ultrasound Elastography (USE) is a CLD assessment imaging method. This study aims to evaluate a recently introduced commercial alternative of USE, Visual Transient Elastography (ViTE), and to compare it with three established USE methods, Vibration Controlled Transient Elastography (VCTE), Shear Wave Elastography (SWE) and Sound Touch Elastography (STE), using Liver Biopsy (LB) as 'Gold Standard'.
View Article and Find Full Text PDFNonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography.
View Article and Find Full Text PDFHERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Aliment Pharmacol Ther
August 2022
Background: Tenofovir alafenamide (TAF) has exhibited a favourable safety profile on estimated glomerular filtration (eGFR) and bone mineral density (BMD), but has not been extensively studied in patients with renal impairment and/or BMD disorders.
Aims: To assess predictors of eGFR changes and other safety and efficacy outcomes during 24-month TAF therapy in patients with chronic hepatitis B with renal and/or BMD disorders/risks.
Methods: Adult patients who started TAF at 13 clinics throughout Greece were prospectively included.